334 related articles for article (PubMed ID: 16896285)
1. Clinical trial design in systemic lupus erythematosus.
Dall'Era M; Wofsy D
Curr Opin Rheumatol; 2006 Sep; 18(5):476-80. PubMed ID: 16896285
[TBL] [Abstract][Full Text] [Related]
2. Design, quality, and bias in randomized controlled trials of systemic lupus erythematosus.
Karassa FB; Tatsioni A; Ioannidis JP
J Rheumatol; 2003 May; 30(5):979-84. PubMed ID: 12734892
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains.
Smolen JS; Strand V; Cardiel M; Edworthy S; Furst D; Gladman D; Gordon C; Isenberg DA; Klippel JH; Petri M; Simon L; Tugwell P; Wolfe F
J Rheumatol; 1999 Feb; 26(2):504-7. PubMed ID: 9972996
[TBL] [Abstract][Full Text] [Related]
4. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus.
Gordon C; Bertsias G; Ioannidis JP; Boletis J; Bombardieri S; Cervera R; Dostál C; Font J; Gilboe IM; Houssiau F; Huizinga TW; Isenberg D; Kallenberg CG; Khamashta MA; Piette JC; Schneider M; Smolen JS; Sturfelt G; Tincani A; Van Vollenhoven R; Boumpas DT
Ann Rheum Dis; 2009 Apr; 68(4):470-6. PubMed ID: 18388158
[TBL] [Abstract][Full Text] [Related]
5. Measuring outcomes in systemic lupus erythematosus clinical trials.
Strand V; Chu AD
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):455-68. PubMed ID: 21831027
[TBL] [Abstract][Full Text] [Related]
6. Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials.
Yuen SY; Pope JE
Rheumatology (Oxford); 2008 Sep; 47(9):1367-72. PubMed ID: 18577549
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future--the EULAR recommendations for the management of SLE and the use of end-points in clinical trials.
Bertsias G; Gordon C; Boumpas DT
Lupus; 2008 May; 17(5):437-42. PubMed ID: 18490423
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of systemic lupus erythematosus.
O'Neill SG; Schrieber L
Autoimmun Rev; 2005 Jul; 4(6):395-402. PubMed ID: 16081031
[TBL] [Abstract][Full Text] [Related]
9. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events.
Murdaca G; Colombo BM; Puppo F
Autoimmun Rev; 2011 Nov; 11(1):56-60. PubMed ID: 21835271
[TBL] [Abstract][Full Text] [Related]
10. Factors determining participation in prevention trials among systemic lupus erythematosus patients: a qualitative study.
Costenbader KH; Brome D; Blanch D; Gall V; Karlson E; Liang MH
Arthritis Rheum; 2007 Feb; 57(1):49-55. PubMed ID: 17266094
[TBL] [Abstract][Full Text] [Related]
11. Re-evaluation of biologic therapies in systemic lupus erythematosus.
Bruce IN
Curr Opin Rheumatol; 2010 May; 22(3):273-7. PubMed ID: 20177385
[TBL] [Abstract][Full Text] [Related]
12. Biologics in the treatment of systemic lupus erythematosus.
Lateef A; Petri M
Curr Opin Rheumatol; 2010 Sep; 22(5):504-9. PubMed ID: 20502332
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial design in systemic lupus erythematosus: lessons learned and future directions.
Strand V
Lupus; 2004; 13(5):406-11. PubMed ID: 15230300
[TBL] [Abstract][Full Text] [Related]
14. The role of exercise in the rehabilitation of patients with systemic lupus erythematosus and patients with primary Sjögren's syndrome.
Strömbeck B; Jacobsson LT
Curr Opin Rheumatol; 2007 Mar; 19(2):197-203. PubMed ID: 17278938
[TBL] [Abstract][Full Text] [Related]
15. Blinding protocols, treatment credibility, and expectancy: methodologic issues in clinical trials of osteopathic manipulative treatment.
Licciardone JC; Russo DP
J Am Osteopath Assoc; 2006 Aug; 106(8):457-63. PubMed ID: 16943515
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?
Schiffenbauer J; Simon LS
Lupus; 2004; 13(5):398-405. PubMed ID: 15230299
[TBL] [Abstract][Full Text] [Related]
17. B-cell-directed therapies in systemic lupus erythematosus.
Tieng AT; Peeva E
Semin Arthritis Rheum; 2008 Dec; 38(3):218-27. PubMed ID: 18206214
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutics for systemic lupus erythematosus.
Wiesendanger M; Stanevsky A; Kovsky S; Diamond B
Curr Opin Rheumatol; 2006 May; 18(3):227-35. PubMed ID: 16582684
[TBL] [Abstract][Full Text] [Related]
19. Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past.
Booth CM
Clin Cancer Res; 2010 Dec; 16(24):5963-71. PubMed ID: 21169249
[TBL] [Abstract][Full Text] [Related]
20. Use of rituximab in patients with systemic lupus erythematosus: an update.
García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Galarza-Maldonado C; Sandoval-Cruz M; Zamudio-Huerta L; López-Colombo A; Cervera R
Autoimmun Rev; 2009 Feb; 8(4):343-8. PubMed ID: 19036350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
